

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

28 March 2019 (28.03.2019)



(10) International Publication Number

WO 2019/057974 A1

(51) International Patent Classification:

C07K 14/005 (2006.01) C12N 7/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2018/075824

(22) International Filing Date:

24 September 2018 (24.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17306255.5 22 September 2017 (22.09.2017) EP

(71) Applicants: **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)** [FR/FR]; 3, rue Michel Ange, 75016 PARIS (FR). **UNIVERSITE PARIS-SUD** [FR/FR]; 15, rue Georges Clémenceau, 91400 ORSAY (FR).

(72) Inventors: **ALBERTINI, Aurélie**; 3, avenue Pierre Curie, 91940 GOMETZ LE CHATEL (FR). **GAUDIN, Yves**; 4, rue Léon Delagrangé, 75015 PARIS (FR). **RAUX, Hélène**; 1, allée des impressionnistes, 92160 ANTONY (FR). **BELOT, Laura**; 11, rue des fougères, 78310 MAUREPAS (FR). **NIKOLIC, Jovan**; 326, rue Lecourbe, 75015 PARIS (FR).

(74) Agent: **REGIMBEAU**; 20, rue de Chazelles, 75847 PARIS CEDEX 17 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MUTATED GLYCOPROTEIN OF VESICULAR STOMATITIS VIRUS

(57) Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO : 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.



MUTATED GLYCOPROTEIN OF VESICULAR STOMATITIS VIRUS

The invention relates to a mutated viral protein, in particular a mutated protein originating from an oncolytic virus.

5 Vesicular stomatitis virus (VSV) is an enveloped, negative-strand RNA virus that belongs to the Vesiculovirus genus of the Rhabdovirus family. It is an arbovirus which can infect insects, cattle, horses and pigs. In mammals, its ability to infect and kill tumor cells while sparing normal cells makes it a promising oncolytic virus for the treatment of cancer (Barber, 2005; Fernandez et al., 2002; Hastie et al., 2013).

10 VSV genome encodes five structural proteins among which a single transmembrane glycoprotein (G). The glycoprotein is a classic type I membrane glycoprotein with an amino-terminal signal peptide, an ectodomain of about 450 amino acids, a single alpha helical transmembrane segment and a small intraviral carboxy-terminal domain. The signal peptide is cleaved in the lumen of the endoplasmic reticulum and the native
15 glycoprotein consists in the ectodomain, the transmembrane domain and the intraviral domain.

G plays a critical role during the initial steps of virus infection (Albertini et al., 2012b). First, it is responsible for virus attachment to specific receptors. After binding, virions enter the cell by a clathrin-mediated endocytic pathway. In the acidic environment of the
20 endocytic vesicle, G triggers the fusion between the viral and endosomal membranes, which releases the genome in the cytosol for the subsequent steps of infection. Fusion is catalyzed by a low-pH-induced large structural transition from a pre- toward a post-fusion conformation which are both trimeric (Roche et al., 2006; Roche et al., 2007).

The polypeptide chain of G ectodomain folds into three distinct domains which are the
25 fusion domain (FD), the pleckstrin homology domain (PHD), and the trimerization domain (TrD). During the structural transition, the FD, the PHD and the TrD retain their tertiary structure. Nevertheless, they undergo large rearrangements in their relative orientation due to secondary changes in hinge segments (S1 to S5) which refold during the low-pH induced conformational change (Roche et al., 2006; Roche et al., 2007).

30 Recently, it has been shown that low-density lipoprotein receptor (LDL-R) and other members of this receptor family serve as VSV receptors (Finkelshtein et al., 2013).

The LDL-R is a type I transmembrane protein which regulates cholesterol homeostasis in mammalian cells (Brown and Goldstein, 1986). LDL-R removes cholesterol carrying lipoproteins from plasma circulation. Ligands bound extracellularly by LDL-R at neutral
35 pH are internalized and then released in the acidic environment of the endosomes leading to their subsequent lysosomal degradation. The receptor then recycles back to the cell surface. LDL-R ectodomain is composed of a ligand-binding domain, an epidermal

growth factor (EGF) precursor homology domain and a C-terminal domain enriched in O-linked oligosaccharides. The ligand binding domain is made of 7 cysteine-rich repeats (CR1 to CR7, **Fig. 1**). Each repeat is made of approximately 40 amino acids and contains 6 cysteine residues, engaged in 3 disulfide bridges, and an acidic residues cluster that coordinates a Ca^{2+} ion. The intracellular release of the cargo is driven by a low-pH-induced conformational change of LDL-R from an open to a closed conformation.

The LDL-R gene family consists of trans-membrane receptors that reside on the cell-surface, are involved in endocytic uptake of lipoproteins, and require Ca^{2+} for ligand binding. All these receptors have in common several CR repeats (up to several tens), EGF precursor-like repeats, a membrane-spanning region and an intracellular domain containing at least one internalization signal sequence. They are found ubiquitously in all animals including insects.

VSV-G has been widely used for pseudotyping other viruses and VSV-G-pseudotyped lentiviruses (VSV-G-LVs) exhibit the same broad tropism as VSV.

On the other hand, VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and hematopoietic stem cells, as they have a very low expression level of LDL-R (Amirache et al., 2014).

The broad tropism of VSV and VSV-G LVs, due to the ubiquitous distribution of the LDL-R receptor family members, is a limitation of their therapeutic use. This is particularly the case in oncotherapy when one wants to target specifically tumor cells.

One aim of the invention is to obviate this drawback.

One aim of the invention is to provide a new mutated VSV-G protein deficient in one of its properties in order to specifically target this protein.

Another aim of the invention is to provide a new VSV expressing such a protein and its use in oncotherapy.

The invention relates to an isolated non-naturally occurring protein comprising, consisting essentially of or consisting of the amino acid sequence as set forth in SEQ ID NO : 1, which corresponds to (which is) the amino acid sequence of the ectodomain of VSV Indiana strain,

wherein at least one of the amino acids at positions 8, 47, 209 and 354, said numbering being made from the position of the first amino acid in the sequence SEQ ID NO:1, is substituted by an amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1,

or any homologous protein derived from said protein as set forth in SEQ ID NO:1 by substitution, addition or deletion of at least one amino acid, provided that the derived protein retains at least 70 % of identity with the amino acid sequence as set forth in SEQ ID NO : 1, and said derived protein retaining the ability to induce membrane fusion and

retaining the ability to interact with LDL membrane receptor,

wherein at least one amino acid, of said homologous protein located at a position equivalent to the positions 8, 47, 209 and 354 of said sequence SEQ ID NO : 1, is substituted by an amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID NO:1,

said isolated non-naturally occurring protein retaining the ability to induce membrane fusion and being unable to interact with LDL membrane receptor.

In a preferred embodiment, the amino acid at position 8 in SEQ ID NO : 1 of the isolated non-naturally occurring protein of invention (said numbering being made from the position of the first amino acid in the sequence SEQ ID NO: 1), or at the position equivalent in the homologous protein derived from said protein as set forth in SEQ ID NO:1 of the invention, cannot be a Y residue.

In a preferred embodiment, the amino acid at position 209 in SEQ ID NO : 1 of the isolated non-naturally occurring protein of invention (said numbering being made from the position of the first amino acid in the sequence SEQ ID NO: 1), or at the position equivalent in the homologous protein derived from said protein as set forth in SEQ ID NO:1 of the invention, cannot be a H residue.

Thus, in other words, the invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO : 1, which corresponds to (which is) the amino acid sequence of the ectodomain of VSV Indiana strain,

wherein at least one of the amino acids at positions 8, 47, 209 and 354, said numbering being made from the position of the first amino acid in the sequence SEQ ID NO: 1, is substituted by an amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1,

wherein the substitution at position 8 is by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1, except Y, and

wherein the substitution at position 209 is by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1, except H,

or any homologous protein derived from said protein as set forth in SEQ ID NO : 1 by substitution, addition or deletion of at least one amino acid, provided that the derived protein retains at least 70 % of identity with the amino acid sequence as set forth in SEQ ID NO : 1, and said derived protein retaining the ability to induce membrane fusion and retaining the ability to interact with LDL membrane receptor,

wherein at least one amino acid, of said homologous protein located at a position equivalent to the positions 8, 47, 209 and 354 of said sequence SEQ ID NO : 1, is substituted by an amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1,

wherein the substitution of the amino acid located at a position equivalent to the position 8 is by any amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1, except Y, and

5 wherein the substitution of the amino acid located at a position equivalent to the position 209 is by any amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1, except H,

said isolated non-naturally occurring protein retaining the ability to induce membrane fusion and being unable to interact with LDL membrane receptor.

10 Advantageously, the invention relates to an isolated non-naturally occurring protein comprising, consisting essentially of or consisting of the amino acid sequence as set forth in SEQ ID NO : 1, which corresponds to (which is) the amino acid sequence of the ectodomain of VSV Indiana strain,

15 wherein the amino acid at position 8, or at position 47, or at position 209, or at position 354, or at both positions 8 and 47, or at both positions 8 and 209, or at both positions 8 and 354, or at both positions 47 and 209, or at both positions 47 and 354, or at both positions 209 and 354, or at the positions 8 and 47 and 209, or at the positions 8 and 47 and 354, or at the positions 8 and 209 and 354, or at the positions 47 and 209 and 354, or at the position 8 and 47 and 209 and 354, said numbering being made from the position
20 of the first amino acid in the sequence SEQ ID NO:1, are substituted by any amino acid different from the amino acid found in SEQ ID NO : 1,

or any homologous protein derived from said protein as set forth in SEQ ID NO:1 by substitution, addition or deletion of at least one amino acid, provided that the derived protein retains at least 70 % of identity with the amino acid sequence as set forth in SEQ
25 ID NO : 1, and said derived protein retaining the ability to induce membrane fusion and retaining the ability to interact with LDL membrane receptor,

30 wherein the amino acid, of said homologous protein, located at a position equivalent to position 8, or to position 47, or to position 209, or to position 354, or to both positions 8 and 47, or to both positions 8 and 209, or to both positions 8 and 354, or to both positions 47 and 209, or to both positions 47 and 354, or to both positions 209 and 354, or to the positions 8 and 47 and 209, or to the positions 8 and 47 and 354, or at the positions 8 and 209 and 354, or to the positions 47 and 209 and 354, or to the position 8 and 47 and 209 and 354, are substituted by any amino acid different from the amino acid found in SEQ ID NO : 1,

35 in particular the amino acid at position 8 is substituted by any amino acid except H, and preferably except Y,

the amino acid at position 47 is substituted by any amino acid except K,

the amino acid at position 209 is substituted by any amino acid except Y and preferably except H,

the amino acid at position 354 is substituted by any amino acid except R,

the numbering being made from the position of the first amino acid in the sequence

5 SEQ ID NO : 1,

said isolated non-naturally occurring protein retaining the ability to induce membrane fusion and being unable to interact with LDL membrane receptor.

Advantageously, the invention relates to an isolated non-naturally occurring protein comprising or consisting essentially of or consisting of the amino acid sequence as set

10 forth in SEQ ID NO: 1,

```

KFTIIVFPHNQKGNWKNVPSNYHYCPSSDLNWHNDLIGTAIQVKMPKSHKAIQADGW
MCHASKWVTTCDERWYGPKYITQSIRSFTPSVEQCKESIETKQGTWLNPGFPPQSC
GYATVTDAAEAVIVQVTPHHVLVDEYTGIEWVDSQFINGKCSNYICPTVHNSTTWHS DY
KVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMOMYCKHWGV
15 RLP SGVWEEMADKDLFAAARFPECPEGSSIAPPSQTSVDVSLIQDVERILDYSLCQET
WSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFFETRYIRVDIAAPIILSRMV
GMISGTTTERELWDDWAPYEDVEIGPNGVLRITSSGYKFFPLYMIGHGMLDSDLHLSSK
AQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSWKS SIASFFFIIGLI
IGLFLVLRVGIHLCKIKLHTKKRQIYTDIEMNRLGK

```

20 or any protein derived from said protein as set forth in SEQ ID NO : 1 by substitution, addition or deletion of at least one amino acid, provided that said protein derived protein derived from said protein as set forth in SEQ ID NO : 1 retains the boxed amino acids as shown above,

wherein the amino acid at position 8, or at position 47, or at position 209, or at position 25 354, or at both positions 8 and 47, or at both positions 8 and 209, or at both positions 8 and 354, or at both positions 47 and 209, or at both positions 47 and 354, or at both positions 209 and 354, or at the positions 8 and 47 and 209, or at the positions 8 and 47 and 354, or at the positions 8 and 209 and 354, or at the positions 47 and 209 and 354, or at the position 8 and 47 and 209 and 354, or the corresponding positions in the protein 30 derived from said protein as set forth in SEQ ID NO : 1, are substituted by any amino acid different from the amino acid found in SEQ ID NO : 1,

in particular the amino acid at position 8 is substituted by any amino acid except H, and preferably except Y,

the amino acid at position 47 is substituted by any amino acid except K,

35 the amino acid at position 209 is substituted by any amino acid except Y and preferably except H,

the amino acid at position 354 is substituted by any amino acid except R,
the numbering being made from the position of the first amino acid in the sequence
SEQ ID NO : 1,

said isolated non-naturally occurring protein retaining the ability to induce membrane
5 fusion and is unable to interact with LDL membrane receptor.

Advantageously, the invention relates to an isolated non-naturally occurring protein
comprising, consisting essentially of or consisting of the amino acid sequence as set forth
in SEQ ID NO : 1, which corresponds to (which is) the amino acid sequence of the
10 ectodomain of VSV Indiana strain,

wherein the amino acid at position 47 or at position 354, or at both positions 47 and
354, said numbering being made from the position of the first amino acid in the sequence
SEQ ID NO:1, are substituted by any amino acid, in particular by any amino acid except
K or R,

15 or any homologous protein derived from said protein as set forth in SEQ ID NO:1 by
substitution, addition or deletion of at least one amino acid, provided that the derived
protein retains at least 70 % of identity with the amino acid sequence as set forth in SEQ
ID NO : 1, and said derived protein retaining the ability to induce membrane fusion and
retaining the ability to interact with LDL membrane receptor,

20 wherein the amino acid, of said homologous protein, located at a position equivalent
to position 47 or to position 354, or to both positions 47 and 354, are substituted by any
amino acid, in particular any amino acid except K or R,

the numbering being made from the position of the first amino acid in the sequence
SEQ ID NO : 1,

25 said isolated non-naturally occurring protein retaining the ability to induce membrane
fusion and being unable to interact with LDL membrane receptor.

In one embodiment, said isolated non-naturally occurring protein further comprises a
substitution of the amino acid at position 8, or at position 209, or at both positions 8 and
209, by any amino acid, said numbering being made from the position of the first amino
30 acid in the sequence SEQ ID NO:1,

preferably wherein the amino acid at position 8 is substituted by any amino acid except
H or Y, and

preferably wherein the amino acid at position 209 is substituted by any amino acid
except H or Y.

35 Advantageously, the invention relates to an isolated non-naturally occurring protein as
defined above comprising, consisting essentially of or consisting of the amino acid
sequence as set forth in SEQ ID NO : 1,

KFTIVFPHNQKGNWKNVPSNYHYCPSSDLNWHNDLIGTAIQVKMPKSHKAIQADGW
 MCHASKWVTTCDFRWYGPKYITQSI RSFTPSVEQCKESI EQTKQGTWLNPGFPPQSC
 GYATVTDAEAVIVQVTPHHVLVDEYTGFWVDSQFINGKCSNYICPTVHNSTTWHSDY
 KVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAFETGGKACKM QYCKHWGV
 5 RLP SGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQET
 WSKIRAGLPISPVDLSYLA PKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMV
 GMISGTTTERELWDDWAPYEDVEIGPNGVLR TSSGYKFPLYMIGHGMLDSDLHLSSK
 AQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSWKSSIASFFFIIGLI
 IGLFLVLRVGIHLCKIKLHTKKRQIYTDIEMNRLGK

10 or any protein derived from said protein as set forth in SEQ ID NO : 1 by substitution, addition or deletion of at least one amino acid, provided that said protein derived protein derived from said protein as set forth in SEQ ID NO : 1 retains the boxed amino acids as shown above,

wherein the amino acid at position 47 or at position 354, or at both positions 47 and
 15 354, or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, are substituted by any amino acid, in particular by any amino acid except K or R,

the numbering being made from the position of the first amino acid in the sequence SEQ ID NO : 1,

20 said isolated non-naturally occurring protein retaining the ability to induce membrane fusion and is unable to interact with LDL membrane receptor.

In one embodiment, said isolated non-naturally occurring protein further comprises a
 substitution of the amino acid at position 8, or at position 209, or at both positions 8 and
 25 209, by any amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1 or at the position equivalent in said homologous protein, said numbering being made from the position of the first amino acid in the sequence SEQ ID NO:1,

preferably wherein the amino acid at position 8 is substituted by any amino acid except H or Y, and

30 preferably wherein the amino acid at position 209 is substituted by any amino acid except H or Y.

The invention is based on the unexpected observation made by the inventors that a
 substitution of at least one amino acid residues at positions 8, 47, 209 or 354, or the
 35 combination of two or three or the four amino acids, affects the ability of VSV G protein to interact with its receptor (LDL membrane receptor) but retain its property to induce

membrane fusion, in particular at low pH.

The invention encompasses proteins containing the amino acid sequence SEQ ID NO : 1, which corresponds to the native form of the Indiana strain of VSV, and which lacks the signal peptide. The invention also encompasses any G protein from VSV strains provided that said protein retains the amino acids that are represented with a box in SEQ ID NO : 1.

The G proteins from VSV strains may differ by addition, substitution or insertion of at least one amino acid which are not the amino acid represented with a box in SEQ ID NO : 1.

Regarding the numbering of the amino acid, this numbering is in the invention conventionally based on the numbering of the amino acids of the native form of the G protein of VSV G Indiana as set forth in SEQ ID NO : 1. The skilled person knows the sequence alignment algorithms and programs (ClustalW for instance) and could easily compare the sequences of different G proteins and recalculate the exact position for a determined G protein compared to the numbering obtained in SEQ ID NO : 1. For sake of clarity, the amino acid at positions 8, 47, 209 and 354 are indicated in bold in the above SEQ ID NO : 1.

The invention encompasses proteins containing the amino acid sequence SEQ ID NO: 1. The invention also encompasses any homologous G protein from VSV strains provided that said protein retains at least 70 % of identity with the amino acid sequence SEQ ID NO : 1.

By "at least 70% of identity", it is meant in the invention 70 %, 71 %, 72 %, 73 %, 74 %, 75 %, 76 %, 77 %, 78 %, 79 %, 80 %, 81 %, 82 %, 83 %, 84 %, 85 %, 86 %, 87 %, 88 %, 89 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % and 100 % of identity with the sequence SEQ ID NO : 1.

Regarding the percentage of identity, it is defined by the percentage of amino acid residues of SEQ ID NO : 1 which align with the same amino acid in the sequence of the homologous protein. The sequence alignment is performed using dedicated algorithms and programs (such as ClustalW, for instance).

Therefore, the protein according to the invention may derive from the following amino acid sequences:

- SEQ ID NO : 2, the full length VSV G protein from Indiana strain, by substitution of the amino acids at position 63, or at position 370, or both by any amino acid except K or R,
- SEQ ID NO : 3, the ectodomain of the VSV G protein from Marraba strain, by substitution of the amino acids at position 47, or at position 354, or both by any amino acid except K or R,

- SEQ ID NO : 4, the full length VSV G protein from Marraba strain, by substitution of the amino acids at position 63, or at position 370, or both by any amino acid except K or R,
- 5 - SEQ ID NO : 5, the ectodomain of the VSV G protein from New Jersey strain, by substitution of the amino acids at position 47, or at position 358, or both by any amino acid except K or R,
- SEQ ID NO : 6, the full length VSV G protein from New Jersey strain, by substitution of the amino acids at position 63, or at position 374, or both by any amino acid except K or R,
- 10 - SEQ ID NO : 7, the ectodomain of the VSV G protein from Carajas strain, by substitution of the amino acids at position 47, or at position 358, or both by any amino acid except K or R,
- SEQ ID NO : 8, the full length VSV G protein from Carajas strain, by substitution of the amino acids at position 63, or at position 374, or both by any amino acid except K or R,
- 15 - SEQ ID NO : 9, the ectodomain of the VSV G protein from Alagoa strain, by substitution of the amino acids at position 47, or at position 354, or both by any amino acid except K or R,
- SEQ ID NO : 10, the full length VSV G protein from Alagoa strain, by substitution of the amino acids at position 64, or at position 371, or both by any amino acid except K or R,
- 20 - SEQ ID NO : 11, the ectodomain of the VSV G protein from Cocal strain, by substitution of the amino acids at position 47, or at position 354, or both by any amino acid except K or R, and
- 25 - SEQ ID NO : 12, the full length VSV G protein from Cocal strain, by substitution of the amino acids at position 64, or at position 371, or both by any amino acid except K or R.
- SEQ ID NO : 13, the ectodomain of the VSV G protein from Morreton strain, by substitution of the amino acids at position 47, or at position 354, or both by any amino acid except K or R, and
- 30 - SEQ ID NO : 14, the full length VSV G protein from Morreton strain, by substitution of the amino acids at position 64, or at position 371, or both by any amino acid except K or R.

Via the crystallographic characterization of the G protein, the inventors showed that
35 residues K47 and R354 are highly critical for the interaction with the LDL derived receptor. When one or both residues are substituted by another amino acid residue have physical and chemical different properties, the resulting G protein loses its capacity to interact with

cellular receptor. By contrast, the same resulting protein, in appropriate condition of pH retains its fusogenic property.

In the invention, the protein is isolated, which means that the protein has been isolated from its natural context. The protein is non-naturally occurring, which means that the only way to obtain this protein is to carry out a substitution, in a laboratory, by using technological methods man-made, well known in the art.

More advantageously, the invention relates to the isolated non-naturally occurring protein previously disclosed, wherein said protein comprises, or consists essentially of or consists of one of the following amino acid sequence:

- 10 - SEQ ID NO : 15-20 ;
- SEQ ID NO : 21-26 ;
- SEQ ID NO : 27-32 ;
- SEQ ID NO : 33-38 ;
- SEQ ID NO : 39-44 ;
- 15 - SEQ ID NO : 45-50 ; and
- SEQ ID NO : 51-56,

wherein the amino acid at position 47 or at position 354, or at both positions 47 and 354, or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, are any amino acid except K or R. In other words, in the invention the amino acids Xaa corresponds to any amino acid except R or K.

SEQ ID NO : 15 corresponds to the ectodomain of the VSV G protein from Indiana strain having a substitution at position 47, by any amino acid except K or R.

SEQ ID NO : 16 corresponds to the ectodomain of the VSV G protein from Indiana strain having a substitution at position 354, by any amino acid except K or R.

25 SEQ ID NO : 17 corresponds to the ectodomain of the VSV G protein from Indiana strain having a substitution at positions 47 and 354, by any amino acid except K or R.

SEQ ID NO : 18 corresponds to the full length VSV G protein from Indiana strain having a substitution at position 63, by any amino acid except K or R.

30 SEQ ID NO : 19 corresponds to the full length VSV G protein from Indiana strain having a substitution at position 370, by any amino acid except K or R.

SEQ ID NO : 20 corresponds to the full length VSV G protein from Indiana strain having a substitution at positions 63 and 370, by any amino acid except K or R.

SEQ ID NO : 21 corresponds to the ectodomain of the VSV G protein from Marraba strain having a substitution at position 47, by any amino acid except K or R.

35 SEQ ID NO : 22 corresponds to the ectodomain of the VSV G protein from Marraba strain having a substitution at position 354, by any amino acid except K or R.

SEQ ID NO : 23 corresponds to the ectodomain of the VSV G protein from Marraba

strain having a substitution at positions 47 and 354, by any amino acid except K or R.

SEQ ID NO : 24 corresponds to the full length VSV G protein from Marraba strain having a substitution at position 63, by any amino acid except K or R.

5 SEQ ID NO : 25 corresponds to the full length VSV G protein from Marraba strain having a substitution at position 370, by any amino acid except K or R.

SEQ ID NO : 26 corresponds to the full length VSV G protein from Marraba strain having a substitution at positions 63 and 370, by any amino acid except K or R.

SEQ ID NO : 27 corresponds to the ectodomain of the VSV G protein from New Jersey strain having a substitution at position 47, by any amino acid except K or R.

10 SEQ ID NO : 28 corresponds to the ectodomain of the VSV G protein from New Jersey strain having a substitution at position 358, by any amino acid except K or R.

SEQ ID NO : 29 corresponds to the ectodomain of the VSV G protein from New Jersey strain having a substitution at positions 47 and 358, by any amino acid except K or R.

15 SEQ ID NO : 30 corresponds to the full length VSV G protein from New Jersey strain having a substitution at position 63, by any amino acid except K or R.

SEQ ID NO : 31 corresponds to the full length VSV G protein from New Jersey strain having a substitution at position 374, by any amino acid except K or R.

SEQ ID NO : 32 corresponds to the full length VSV G protein from New Jersey strain having a substitution at positions 63 and 374, by any amino acid except K or R.

20 SEQ ID NO : 33 corresponds to the ectodomain of the VSV G protein from Carajas strain having a substitution at position 47, by any amino acid except K or R.

SEQ ID NO : 34 corresponds to the ectodomain of the VSV G protein from Carajas strain having a substitution at position 358, by any amino acid except K or R.

25 SEQ ID NO : 35 corresponds to the ectodomain of the VSV G protein from Carajas strain having a substitution at positions 47 and 358, by any amino acid except K or R.

SEQ ID NO : 36 corresponds to the full length VSV G protein from Carajas strain having a substitution at position 68, by any amino acid except K or R.

SEQ ID NO : 37 corresponds to the full length VSV G protein from Carajas strain having a substitution at position 379, by any amino acid except K or R.

30 SEQ ID NO : 38 corresponds to the full length VSV G protein from Carajas strain having a substitution at positions 68 and 379, by any amino acid except K or R.

SEQ ID NO : 39 corresponds to the ectodomain of the VSV G protein from Alagoa strain having a substitution at position 47, by any amino acid except K or R.

35 SEQ ID NO : 40 corresponds to the ectodomain of the VSV G protein from Alagoa strain having a substitution at position 354, by any amino acid except K or R.

SEQ ID NO : 41 corresponds to the ectodomain of the VSV G protein from Alagoa strain having a substitution at positions 47 and 354, by any amino acid except K or R.

SEQ ID NO : 42 corresponds to the full length VSV G protein from Alagoa strain having a substitution at position 64, by any amino acid except K or R.

SEQ ID NO : 43 corresponds to the full length VSV G protein from Alagoa strain having a substitution at position 371, by any amino acid except K or R.

5 SEQ ID NO : 44 corresponds to the full length VSV G protein from Alagoa strain having a substitution at positions 64 and 371, by any amino acid except K or R.

SEQ ID NO : 45 corresponds to the ectodomain of the VSV G protein from Cocal strain having a substitution at position 47, by any amino acid except K or R.

10 SEQ ID NO : 46 corresponds to the ectodomain of the VSV G protein from Cocal strain having a substitution at position 354, by any amino acid except K or R.

SEQ ID NO : 47 corresponds to the ectodomain of the VSV G protein from Cocal strain having a substitution at positions 47 and 354, by any amino acid except K or R.

SEQ ID NO : 48 corresponds to the full length VSV G protein from Cocal strain having a substitution at position 64, by any amino acid except K or R.

15 SEQ ID NO : 49 corresponds to the full length VSV G protein from Cocal strain having a substitution at position 371, by any amino acid except K or R.

SEQ ID NO : 50 corresponds to the full length VSV G protein from Cocal strain having a substitution at positions 64 and 371, by any amino acid except K or R.

20 SEQ ID NO : 51 corresponds to the ectodomain of the VSV G protein from Morreton strain having a substitution at position 47, by any amino acid except K or R.

SEQ ID NO : 52 corresponds to the ectodomain of the VSV G protein from Morreton strain having a substitution at position 354, by any amino acid except K or R.

SEQ ID NO : 53 corresponds to the ectodomain of the VSV G protein from Morreton strain having a substitution at positions 47 and 354, by any amino acid except K or R.

25 SEQ ID NO : 54 corresponds to the full length VSV G protein from Morreton strain having a substitution at position 64, by any amino acid except K or R.

SEQ ID NO : 55 corresponds to the full length VSV G protein from Morreton strain having a substitution at position 371, by any amino acid except K or R.

30 SEQ ID NO : 56 corresponds to the full length VSV G protein from Morreton strain having a substitution at positions 64 and 371, by any amino acid except K or R.

In other word, the invention relates advantageously to an isolated non-naturally occurring protein comprising or consisting of one the following sequences SEQ ID NO : 15-56, wherein Xaa corresponds to any amino acid expect R or K.

35 Advantageously, the invention relates to the isolated non-naturally occurring protein as defined above, wherein the amino acid at position 47 or at position 354, or at both positions 47 and 354 are substituted by A, G, F or Q, preferably A or Q.

In other word, the invention relates advantageously to an isolated non-naturally

occurring protein comprising or consisting of one the following sequences: SEQ ID NO : 15-56, wherein Xaa corresponds to any amino acid expect R or K.

Advantageously, the invention relates to an isolated protein comprising, consisting essentially of, or consisting of one of the following sequences SEQ ID NO : 155-322. In
5 other words, the invention relates advantageously to an isolated protein as defined above comprising, consisting essentially of, or consisting of one of the following sequences SEQ ID NO : 155, SEQ ID NO : 156, SEQ ID NO : 157, SEQ ID NO : 158, SEQ ID NO : 159, SEQ ID NO : 160, SEQ ID NO : 161, SEQ ID NO : 162, SEQ ID NO : 163, SEQ ID NO : 164, SEQ ID NO : 165, SEQ ID NO : 166, SEQ ID NO : 167, SEQ ID NO : 168, SEQ ID
10 NO : 169, SEQ ID NO : 170, SEQ ID NO : 171, SEQ ID NO : 172, SEQ ID NO : 173, SEQ ID NO : 174, SEQ ID NO : 175, SEQ ID NO : 176, SEQ ID NO : 177, SEQ ID NO : 178, SEQ ID NO : 179, SEQ ID NO : 180, SEQ ID NO : 181, SEQ ID NO : 182, SEQ ID NO : 183, SEQ ID NO : 184, SEQ ID NO : 185, SEQ ID NO : 186, SEQ ID NO : 187, SEQ ID NO : 188, SEQ ID NO : 189, SEQ ID NO : 190, SEQ ID NO : 191, SEQ ID NO : 192, SEQ
15 ID NO : 193, SEQ ID NO : 194, SEQ ID NO : 195, SEQ ID NO : 196, SEQ ID NO : 197, SEQ ID NO : 198, SEQ ID NO : 199, SEQ ID NO : 200, SEQ ID NO : 201, SEQ ID NO : 202, SEQ ID NO : 179, SEQ ID NO : 180, SEQ ID NO : 181, SEQ ID NO : 182, SEQ ID NO : 183, SEQ ID NO : 184, SEQ ID NO : 185, SEQ ID NO : 186, SEQ ID NO : 187, SEQ ID NO : 188, SEQ ID NO : 189, SEQ ID NO : 190, SEQ ID NO : 191, SEQ ID NO : 192,
20 SEQ ID NO : 193, SEQ ID NO : 194, SEQ ID NO : 195, SEQ ID NO : 196, SEQ ID NO : 197, SEQ ID NO : 198, SEQ ID NO : 199, SEQ ID NO : 200, SEQ ID NO : 201, SEQ ID NO : 202, SEQ ID NO : 203, SEQ ID NO : 204, SEQ ID NO : 205, SEQ ID NO : 206, SEQ ID NO : 207, SEQ ID NO : 208, SEQ ID NO : 209, SEQ ID NO : 210, SEQ ID NO : 211, SEQ ID NO : 212, SEQ ID NO : 213, SEQ ID NO : 214, SEQ ID NO : 215, SEQ ID NO :
25 216, SEQ ID NO : 217, SEQ ID NO : 218, SEQ ID NO : 219, SEQ ID NO : 220, SEQ ID NO : 221, SEQ ID NO : 222, SEQ ID NO : 223, SEQ ID NO : 224, SEQ ID NO : 225, SEQ ID NO : 226, SEQ ID NO : 227, SEQ ID NO : 228, SEQ ID NO : 229, SEQ ID NO : 230, SEQ ID NO : 231, SEQ ID NO : 232, SEQ ID NO : 233, SEQ ID NO : 234, SEQ ID NO : 235, SEQ ID NO : 236, SEQ ID NO : 237, SEQ ID NO : 238, SEQ ID NO : 239, SEQ ID
30 NO : 240, SEQ ID NO : 241, SEQ ID NO : 242, SEQ ID NO : 243, SEQ ID NO : 244, SEQ ID NO : 245, SEQ ID NO : 246, SEQ ID NO : 247, SEQ ID NO : 248, SEQ ID NO : 249, SEQ ID NO : 250, SEQ ID NO : 251, SEQ ID NO : 252, SEQ ID NO : 253, SEQ ID NO : 254, SEQ ID NO : 255, SEQ ID NO : 256, SEQ ID NO : 257, SEQ ID NO : 258, SEQ ID NO : 259, SEQ ID NO : 260, SEQ ID NO : 261, SEQ ID NO : 262, SEQ ID NO : 263, SEQ
35 ID NO : 264, SEQ ID NO : 265, SEQ ID NO : 266, SEQ ID NO : 267, SEQ ID NO : 268, SEQ ID NO : 269, SEQ ID NO : 270, SEQ ID NO : 271, SEQ ID NO : 272, SEQ ID NO : 273, SEQ ID NO : 274, SEQ ID NO : 275, SEQ ID NO : 276, SEQ ID NO : 277, SEQ ID

NO : 278, SEQ ID NO : 279, SEQ ID NO : 280, SEQ ID NO : 281, SEQ ID NO : 282, SEQ ID NO : 283, SEQ ID NO : 284, SEQ ID NO : 285, SEQ ID NO : 286, SEQ ID NO : 287, SEQ ID NO : 288, SEQ ID NO : 289, SEQ ID NO : 290, SEQ ID NO : 291, SEQ ID NO : 292, SEQ ID NO : 293, SEQ ID NO : 294, SEQ ID NO : 295, SEQ ID NO : 296, SEQ ID NO : 297, SEQ ID NO : 298, SEQ ID NO : 299, SEQ ID NO : 300, SEQ ID NO : 301, SEQ ID NO : 302, SEQ ID NO : 303, SEQ ID NO : 304, SEQ ID NO : 305, SEQ ID NO : 306, SEQ ID NO : 307, SEQ ID NO : 308, SEQ ID NO : 309, SEQ ID NO : 310, SEQ ID NO : 311, SEQ ID NO : 312, SEQ ID NO : 313, SEQ ID NO : 314, SEQ ID NO : 315, SEQ ID NO : 316, SEQ ID NO : 317, SEQ ID NO : 318, SEQ ID NO : 319, SEQ ID NO : 320, SEQ ID NO : 321 and SEQ ID NO : 322.

More advantageously, the invention relates to the isolated non-naturally occurring protein as defined above, wherein the amino acid at position 8 of SEQ ID NO : 1 or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, is substituted by any amino acid except H or Q or Y.

More advantageously, the invention relates to the isolated non-naturally occurring protein as defined above, wherein the amino acid at position 209 of SEQ ID NO : 1 or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, is substituted by any amino acid except Y or H.

More advantageously, the invention relates to the isolated non-naturally occurring protein as defined above, wherein said protein comprises or consists essentially of one of the following amino acid sequence : SEQ ID NO 57-154.

SEQ ID NO 57-154 represent proteins wherein the amino acid at position 47 or at position 354, or at both positions 47 and 354, or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, are substituted by any amino acid except K or R, and

wherein

- the amino acid at position 8 of SEQ ID NO : 1 or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, is substituted by any amino acid except H or Q or preferably except Y
- the amino acid at position 209 of SEQ ID NO : 1 or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, is substituted by any amino acid except Y or H, or
- the amino acid at position 8 of SEQ ID NO : 1 or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, is substituted by any amino acid except H or Q or preferably except Y and the amino acid at position 209 of SEQ ID NO : 1 or the corresponding positions in the protein derived from said protein as set forth in SEQ ID NO : 1, is substituted by any amino acid except

Y or H.

More advantageously, the invention relates to the isolated non-naturally occurring protein as defined above, further comprising an insertion of a peptide between the amino acids at positions

- 5 192 to 202, or
 240 to 257, or
 347 to 353, or
 364 to 366, or

376 to 379, said peptide originating from a protein different from the protein as set forth
 10 in SEQ ID NO : 1. The inventors identified that an insertion of a peptide, said peptide originating from a protein different from the G protein of VSV, within the above mentioned region does not alter the fusion property of the protein according to the invention.

In the invention, an insertion "between the amino acids positions 192 to 202, 240 to 257, 347 to 353, 364 to 366, or 376 to 379" means that the peptide is inserted

- 15 - either between two consecutive amino acids, for instance between the amino acids at positions 192 and 193, 193 and 194, 194 and 195, 195 and 196, 196 and 197, 197 and 198, 198 and 199, 199 and 200, 200 and 201, 201 and 202, 240 and 241, 241 and 242, 242 and 243, 243 and 244, 244 and 245, 245 and 246, 246 and 247, 247 and 248, 248 and 249, 249 and 250, 250 and 251, 251 and 252, 252 and 253,
 20 253 and 254, 254 and 255, 255 and 256, 256 and 257, 347 and 348, 348 and 349, 349 and 350, 350 and 351, 351 and 352, 352 and 353, 364 and 365, 365 and 366, 376 and 377, 377 and 378, and 378 and 379,
 - or between two non-consecutive numbered amino acids due to a deletion of one or more amino acid ; for instance a peptide can be inserted between the amino acids
 25 at positions 192 and 194, because the amino acid at position 193 was deleted or replaced by the inserted peptide (etc.).

With the above explanations, the skilled person will be able to determine the positions of the insertion encompassed by the invention.

More advantageously, the invention relates to the isolated non-naturally occurring
 30 protein as defined above, further comprising an insertion of a peptide between the amino acids at position 351 and 352, said peptide originating from a protein different from the protein as set forth in SEQ ID NO : 1. Advantageously, the invention relates to the isolated non-naturally occurring protein as defined above, further comprising an insertion of a peptide in position 1 (in other words, at the N-terminal extremity, i.e. upstream of the
 35 amino acid at position 1), said peptide originating from a protein different from the protein as set forth in SEQ ID NO : 1. In the invention, an insertion of a peptide in position 1 means an insertion of said peptide at the N-terminal extremity of the non-naturally

occurring protein as defined above. Thus, in this embodiment, the first amino acid residue of the sequence of said non-naturally occurring protein as defined above is preserved (maintained). In other words, said first amino acid residue at position 1 of the sequence of said non-naturally occurring protein as defined above is not deleted. In an alternative
5 embodiment, the invention relates to the isolated non-naturally occurring protein as defined above, further comprising an insertion of a peptide in replacement of the amino acid residue at position 1, said peptide originating from a protein different from the protein as set forth in SEQ ID NO : 1. Thus, in this alternative embodiment, the first amino acid residue of the sequence of said non-naturally occurring protein as defined above is
10 deleted and replaced (i.e. substituted) with the sequence of said peptide.

Advantageously, the inventors identified that an insertion in position 1 (in other words, at the N-terminal extremity) or between the amino acids 351 and 352 of SEQ ID NO : 1, or the corresponding position in SEQ ID NO : 2 – 14, and having a mutation at the position 47, or 354 or both, or the corresponding position in SEQ ID NO : 2 – 14 does not modify
15 the fusion properties of the mutated protein.

Therefore, the inventors propose to insert in the VSV G protein enable to interact with its receptor, between these two amino acids, a tag peptide, a luminescent, a nanobody or any peptide that recognize specifically a membrane protein.

In other words, and with a specific advantage, the inventors therefore propose to
20 provide a mutated VSV G protein, in which is inserted, between the two above mentioned amino acids, any peptide that would allow a specific targeting of cells of interest.

More advantageously, the invention relates to the isolated non-naturally occurring protein as defined above, wherein said peptide is at least a part of a ligand of a cellular receptor.

25 With the mutated protein according to the invention, in which it is inserted a peptide or a nanobody, it become possible to produce a VSV that specifically target a cell of interest, in particular a tumoral cell, and therefore specifically kill this determined cell by using the oncolytic properties of the virus.

Indeed, in this case, the G protein according to the invention would not interact with
30 its natural receptor (LDL-R) but will recognize a receptor which is a target to the peptide inserted between the amino acids at position 351 and 352 of SEQ ID NO : 1, or the corresponding positions in SEQ ID NO : 2-14. As the protein according to the invention retains its fusogenic properties, the protein would allow the virus entry, and the virus could therefore kill the targeted cell.

35 For instance, the inserted peptide could be an anti-HER2 nanobody, an anti-MUC18 nanobody or an anti-PD-1 nanobody.

The invention also relates to a nucleic acid molecule coding for an isolated non-

naturally occurring protein as defined above.

In other words, the invention relates to a nucleic acid molecule coding for any protein as set forth in SEQ ID NO: 15-322, as defined above.

In another aspect, the invention relates to a recombinant virus expressing an isolated
5 non-naturally occurring protein as defined above. An advantageous virus is a VSV expressing all the viral protein in their wild type form except the G protein which corresponds to the mutated protein according to the invention.

Advantageously, the invention relates to a recombinant virus comprising a nucleic acid molecule as defined above.

10 The invention also relates to a eukaryotic cell containing or expressing a non-naturally occurring protein as defined above, or containing a nucleic acid molecule as defined above. Advantageously, the invention relates to a eukaryotic cell infected by a virus as defined above.

The invention also relates to a composition comprising one at least of the followings:
15 a protein according as defined above; or
a nucleic acid molecule as defined above;
a virus as defined above; or,
a eukaryotic cell as defined above.

In particular, the invention relates to a composition comprising a virus coding for a G
20 protein comprising or consisting of one of the following sequences SEQ ID NO : 15-322.

The invention also relates to a composition comprising one at least of the followings:
a protein according as defined above; or
a nucleic acid molecule as defined above;
a virus as defined above; or,
25 a eukaryotic cell as defined above,
for its use as drug.

In particular, the invention relates to a composition comprising a virus coding for a G protein comprising or consisting of one of the following sequences SEQ ID NO : 15-322, for its use as drug.

30 Advantageously, the invention relates to the composition as defined above, for its use for treating cancer.

As mentioned above, a virus expressing a mutated protein according to the invention can be used to specifically target a determined cell and therefore to specifically kill them.

The invention relates to the *in vitro* use of a protein as defined above, anchored in
35 surface, advantageously, a lipid membrane for targeting said surface, advantageously a lipid membrane, to a specific target, for instance a cell, in particular a cell to be killed, such as a cancer cell.

In the invention, it is proposed to use *in vitro* a protein according to the invention which is anchored to a membrane to specifically address such membrane to a target destination. For instance, the mutated protein according to the invention can be anchored in the membrane of a liposome, of a vesicle, of an exosome, on a capsule, on a nanoparticle ... such that the protein according to the invention can specifically target this liposome, vesicle, capsule or nanoparticle to a specific target, for instance a cell, in particular a cell to be killed, such as a cancer cell.

This use is particularly advantageous in a drug-delivery targeting purpose, wherein the protein according to the invention allow a specific target of a drug.

10 The drug can be a therapeutic molecule, a protein, and a nucleic acid.

The invention relates to a protein as defined above, anchored in a surface, advantageously, a lipid membrane, for use for targeting said surface, advantageously a lipid membrane, to a specific target, for instance a cell, in particular a cell to be killed, such as a cancer cell.

15 In the invention, it is proposed a protein according to the invention which is anchored to a membrane for use to specifically address such membrane to a target destination. For instance, the mutated protein according to the invention can be anchored in the membrane of a liposome, of a vesicle, of an exosome, on a capsule, on a nanoparticle ... such that the protein according to the invention can specifically target this liposome, vesicle, capsule or nanoparticle to a specific target, for instance a cell, in particular a cell to be killed, such as a cancer cell.

This use is particularly advantageous in a drug-delivery targeting purpose, wherein the protein according to the invention allows to specifically target a drug to a specific target, for instance a cell, in particular a cell to be killed, such as a cancer cell.

25 Thus, the invention relates to a mutated protein according to the invention for use as a drug delivery-system, wherein said mutated protein is anchored in the membrane of a liposome, or of a vesicle, or of an exosome, or on a capsule, or on a nanoparticle.

The drug can be a therapeutic molecule, a protein, and a nucleic acid.

30 The invention will be better understood from the following figures and examples.

Legend to the figures

Figure 1 is a schematic representation of the modular organization of the LDL-R indicating the 7 CR modules (1 to 7), the 3 EGF repeats (a b and c), the seven-bladed β -propeller domain (β) of the epidermal growth factor precursor like domain (B.), and the C-terminal domain containing O-linked oligosaccharides (C.). SP = signal peptide; X = transmembrane domain. A.: CR domains and D.: ectodomain.

Figure 2 represents a result of a SDS PAGE analysis of interaction experiments between the 7 GST-CR domains (1-7), bounded to GSH magnetic beads, and Gth at pH 8. C. represents control. The migration position of the proteins are indicated by an arrow: A. : Gth, B. : CRx-GST and D.: GST.

5 **Figure 3** illustrates the experiments presented in figures 6 and figures 7. After 4h of infection, BSR cells were labelled with an antibody directed against VSV nucleoprotein (Anti VSV N) to visualize the infection (green fluorescence) and a GST-CRATTO550 to probe CR domain recognition by the surface displayed glycoprotein (red fluorescence).

Figures 4A-4I are photographs of labelling of G at the surface of BSR cells infected
10 with VSV using fluorescent GST-CR1ATTO550, GST-CR2ATTO550 and GST-CR3ATTO550. At 4h post infection, cells were incubated with the appropriate GST-CRATTO550 at 4°C during 30 minutes prior fixation and permeabilization and then immuno-labelled using an anti-VSV N antibody to visualize the infection. DAPI was used to stain the nuclei. Scale bars 20µm.

15 Figure 4A represents the labelling of cells using anti-VSV N antibody.

Figure 4B represents the labelling of cells using the fluorescent GST-CR1ATTO550.

Figure 4C represent the superposition of the fluorescence in figure 6A and 6B.

Figure 4D represents the labelling of cells using anti-VSV N antibody.

Figure 4E represents the labelling of cells using the fluorescent GST-CR2ATTO550.

20 Figure 4F represent the superposition of the fluorescence in figure 6D and 6E.

Figure 4G represents the labelling of cells using anti-VSV N antibody.

Figure 4H represents the labelling of cells using the fluorescent GST-CR3ATTO550.

Figure 4I represent the superposition of the fluorescence in figure 6G and 6H.

Figure 5 represents representative plots of each Isothermal titration calorimetry (ITC)
25 analyses between Gth and CR1, Gth and CR2, Gth and CR3 at 20°C. Binding parameters were determined by curve fitting analysis with a single-site binding model. The values indicated in the panel are those corresponding to the curves that are presented. Kd values given in the text are means of 3 independent experiments +/- standard errors. B-C Inhibition of VSV infection by soluble forms of CR domains. Upper x- axis : time (min);
30 upper Y-axis : µcal/s; lower x-axis : molar ratio and lower y-axis : kcal.mol⁻¹ of injectant. Left panel : CR1, middle panel : CR2 and right panel : CR3.

Figures 6A-6F represents photographs of BSR cells infected with VSV-eGFP preincubated with GST-CR1, GST-CR2, GST-CR3 (A-C), CR1, CR2, or CR3 monovalent domains (D-F) at the indicated concentrations. Cells were fixed 4h post infection. Only
35 infected cells are expressing eGFP. Neither CR1 nor GST-CR1 construction protect cells from infection. DAPI was used to stain the nuclei. Scale bars 100 µm.

Figure 7 is a tridimensional representation of GthCR2 crystalline structures in ribbon

representation.

Figure 8 is a tridimensional representation of GthCR3 crystalline structures in ribbon representation.

In both complexes the CR domain is nested in the same cavity of G. N- and C-terminal
5 extremities of each CR are indicated. The trimerization domain (TrD) the pleckstrin
homology domain (PHD) and the fusion domain (FD) of Gth are represented.

Figure 9 is a sequence alignment of LDL-R CR2 and CR3. Conserved residues are in
a grey box and similar residues are boxed. Acidic residues involved in the binding of the
Ca²⁺ ion are indicated by I, II, III, and IV. CR residues involved in polar contacts with G
10 are labelled with grey symbols (light grey for CR2 and black for CR3; dots when the
contact is established via the lateral chain and triangles when the contact is established
via the main chain) on each CR sequence. The aromatic residue which protrudes from
the CR modules and establishes hydrophobic interactions with G is indicated by the
arrow.

15 **Figures 10A** corresponds to a close-up view on the Gth-CR interface showing the
docking of G basic residues on the acidic patch of CR2. The G residues H8, K47, Y209
and R354 are involved in the interaction. Residues labels on each CR domain are in italic
letters when the contact is established via the main chain; putative bonds are shown as
light grey dashed lines.

20 **Figure 10B** corresponds to a close-up view on the Gth-CR interface showing the
docking of G basic residues on the acidic patch of CR3. The G residues H8, K47, Y209
and R354 are involved in the interaction. Residues labels on each CR domain are in italic
letters when the contact is established via the main chain; putative bonds are shown as
light grey dashed lines.

25 **Figures 11A-N** represent flow cytometry analysis of the expression of WT and mutant
glycoproteins at the surface of HEK293T cells and of the binding of fluorescent GST-CR2
(A-D and I-K) and GST-CR3 (E-H and L-M). After 24h of transfection, cell surface
expression of WT and mutant G was assessed using monoclonal anti-G antibody 8G5F11
directly on living cells at 4°C during 1h. Cells were then incubated simultaneously with
30 anti-mouse Alexa fluor 488 and the indicated GST-CRATTO550 dye. Cells transfected
with a G construct that was still able to bind GST-CR domains exhibited red fluorescence
due the ATTO550 dye. In each plot, the percentage of ATTO550 positive cells is indicated.

Figure 11A represents the experiment of binding of fluorescent GST-CR2 with WT
glycoprotein.

35 Figure 11B represents the experiment of binding of fluorescent GST-CR2 with the
glycoprotein H8A mutant.

Figure 11C represents the experiment of binding of fluorescent GST-CR2 with the

glycoprotein Y209A mutant.

Figure 11D represents the experiment of binding of fluorescent GST-CR2 with the glycoprotein K47A mutant.

Figure 11E represents the experiment of binding of fluorescent GST-CR3 with WT glycoprotein.

Figure 11F represents the experiment of binding of fluorescent GST-CR3 with the glycoprotein H8A mutant.

Figure 11G represents the experiment of binding of fluorescent GST-CR3 with the glycoprotein Y209A mutant.

Figure 11H represents the experiment of binding of fluorescent GST-CR3 with the glycoprotein K47A mutant.

Figure 11I represents the experiment of binding of fluorescent GST-CR2 with the glycoprotein K47Q mutant.

Figure 11J represents the experiment of binding of fluorescent GST-CR2 with the glycoprotein R354A mutant.

Figure 11K represents the experiment of binding of fluorescent GST-CR2 with the glycoprotein R354Q mutant.

Figure 11L represents the experiment of binding of fluorescent GST-CR3 with the glycoprotein K47Q mutant.

Figure 11M represents the experiment of binding of fluorescent GST-CR3 with the glycoprotein R354A mutant.

Figure 11N represents the experiment of binding of fluorescent GST-CR3 with the glycoprotein R354Q mutant.

Figure 12 is a schematic representation of the cell-cell fusion assay. BSR cells are co-transfected with plasmids expressing VSV G (either WT or mutant G) and P-GFP (a cytoplasmic marker). 24 h post-transfection cells are exposed for 10 min to media adjusted to the indicated pH which is then replaced by DMEM at pH 7.4. The cells are then kept at 37°C for 1 h before fixation. Upon fusion, the P-GFP diffuses in the syncytia.

Figures 13A-13X are photographs corresponding to the results of the experiment described in figure 20.

Figure 13A represents the result of experiments with empty vector at pH 5.0.

Figure 13B represents the result of experiments with empty vector at pH 5.5.

Figure 13C represents the result of experiments with empty vector at pH 6.0.

Figure 13D represents the result of experiments with empty vector at pH 6.5.

Figure 13E represents the result of experiments with empty vector at pH 7.0.

Figure 13F represents the result of experiments with empty vector at pH 7.5.

Figure 13G represents the result of experiments with vector expressing K47A mutant

at pH 5.0.

Figure 13H represents the result of experiments with vector expressing GK47A mutant at pH 5.5.

Figure 13I represents the result of experiments with vector expressing K47A mutant
5 at pH 6.0.

Figure 13J represents the result of experiments with vector expressing K47A mutant at pH 6.5.

Figure 13K represents the result of experiments with vector expressing K47A mutant at pH 7.0.

10 Figure 13L represents the result of experiments with vector expressing K47A mutant at pH 7.5.

Figure 13M represents the result of experiments with vector expressing R354A mutant at pH 5.0.

15 Figure 13N represents the result of experiments with vector expressing R354A mutant at pH 5.5.

Figure 13O represents the result of experiments with vector expressing R354A mutant at pH 6.0.

Figure 13P represents the result of experiments with vector expressing R354A mutant at pH 6.5.

20 Figure 13Q represents the result of experiments with vector expressing R354A mutant at pH 7.0.

Figure 13R represents the result of experiments with vector expressing R354A mutant at pH 7.5.

25 Figure 13M represents the result of experiments with vector expressing WT G protein at pH 5.0.

Figure 13N represents the result of experiments with vector expressing WT G protein at pH 5.5.

Figure 13O represents the result of experiments with vector expressing WT G protein at pH 6.0.

30 Figure 13P represents the result of experiments with vector expressing WT G protein at pH 6.5.

Figure 13Q represents the result of experiments with vector expressing WT G protein at pH 7.0.

35 Figure 13R represents the result of experiments with vector expressing WT G protein at pH 7.5.

Figure 14 represent an analysis of LDL-R expression in wild-type HAP-1 cells (A), LDL-RKO HAP-1 (B) cells and HEK293T (C). The immunoblot was performed on crude

cell extracts and revealed with anti LDL-R (EP1553Y – 1.). Tubulin (tub) was also immunoblotted as a loading control (2.).

Figure 15 is an histogram showing the effect of the RAP protein on the susceptibility of LDL-R deficient HAP-1 cells to VSV-eGFP infection. VSV-eGFP was used to infect HAP-1 (A) and HAP-1 LDL-RKO (B) cells in presence of RAP (grey column) or not (black column). Infectivity was determined by counting the number of cells expressing eGFP using a flow cytometer. Data depict the mean with standard error for experiments performed in triplicate. p values were determined using an unpaired Student t test (* p <0.01; *** non-significant).

Figure 16 is a schematic representation of the generation of VSVΔG-GFP virus pseudotyped with VSV G mutants. Transfected HEK-293T cells expressing mutant G at their surface were infected with VSVΔG-GFP pseudotyped with VSV G wild type. After 16h of infection, VSVΔG-GFP virions pseudotyped with mutant VSV G were harvested from the supernatant.

Figure 17 represents the incorporation of wild type and mutant G in VSVΔG-GFP viral particles. VSVΔG-GFP pseudotyped with the wild type VSV G was used to infect HEK-293T cells transfected with the indicated mutant (MOI 1). At 16h post infection, viral supernatants were collected, concentrated and analyzed by Western blot (using an anti-VSV G and an anti-VSV M antibody).

Figure 18 represents histograms showing the infectivity of VSVΔG-GFP pseudotyped with WT and mutant glycoproteins. VSVΔG-GFP pseudotyped with WT VSV G was used to infect HEK-293T cells previously transfected with the indicated mutated glycoprotein (MOI 1). VSVΔG-GFP viruses pseudotyped by WT or mutant glycoproteins were used to infect HEK-293T, BSR, CHO and S2 cells during 6h; the percentage of infected cells was determined by counting GFP expressing cells by flow cytometry. Data depict the mean with standard error for three independent experiments. Above each bar, the reduction factor of the titer (compared to VSVΔG-GFP, pseudotyped by WT G which was normalized to 1) is indicated.

Figure 19 are photographs of HEK293T cells transfected with a pCAGGS plasmid encoding for VSV glycoprotein modified by the insertion of the mCherry protein in Nterminal extremity (position 1 of the mature protein) and by the insertion of the mCherry protein in between AA 351 and 352. Red fluorescence is present at the cell surface in both case indicating that the protein was correctly refolded and transported through the Golgi apparatus. This suggests that those two positions on G are potentially interesting to insert any peptide.

Examples

Example 1: Structural basis of low-density lipoprotein receptor recognition by VSV glycoprotein

The inventors identified that VSV G is able to independently bind two distinct CR (cysteine-rich) domains (CR2 and CR3) of LDL-R and they report crystal structures of VSV G in complex with those domains. The structures reveal that the binding sites of CR2 and CR3 on G are identical. We show that HAP-1 cells in which the LDL-R gene has been knocked out are still susceptible to VSV infection confirming that VSV G can use receptors other than LDL-R for entry. However, mutations of basic residues, which are key for interaction with LDL-R CR domains, abolish VSV infectivity in mammalian as well as insect cells. This indicates that the only receptors of VSV in mammalian and in insect cells are members of the LDL-R family and that VSV G has specifically evolved to interact with their CR domains.

LDL-R CR2 and CR3 domains bind VSV G and neutralize viral infectivity

The inventors have expressed individually each LDL-R CR domain in fusion with the glutathione S-transferase (GST) in *E. coli*. Each fusion protein was incubated at pH 8 with magnetic beads coated with glutathione before addition of a soluble form of the ectodomain of G (VSV Gth, amino acid (AA) residues 1-422, generated by thermolysine limited proteolysis of viral particles (**Fig. 2**). After 20 minutes of incubation at 4°C, the beads were washed and the associated proteins were analyzed by SDS/PAGE followed by Coomassie blue staining. This revealed that only CR2 and CR3 domains are able to directly bind VSV G (**Fig. 2**) at pH 8. Additionally, GST-CR2 and GST-CR3 (but not GST-CR1) fluorescently labeled with ATTO550 (**Fig. 3 and Fig. 4**) specifically recognized VSV G expressed at the surface of infected cells. The inventors also used isothermal titration calorimetry (ITC) to investigate the binding parameters of CR1, CR2 and CR3 to Gth in solution (**Fig. 5**). Here again, no interaction between G and CR1 was detected. On the other hand, for both CR2 and CR3, the binding reactions appear to be exothermic, show a 1:1 stoichiometry and exhibit similar Kds (4.3 +/- 1 µM for CR3 and 7.3 +/-1.5 µM for CR2).

Furthermore, recombinant soluble CR2 and CR3 domains, either alone or in fusion with GST, are also able to neutralize viral infectivity when incubated with the viral inoculum prior infection (**Figs. 6**).

Crystal structures of VSV G ectodomain in complex with LDL-R CR domains

The inventors crystallized Gth in complex with either CR2 or CR3. The binding site of CR domains on G is the same in both crystal forms (**Fig.7 and Fig. 8**).

Two basic residues of G (H8 from the TrD and K47 from PHD) are pointing toward two acidic residues which belong to the octahedral calcium cage of the CR domains (D69 and

D73 on CR2; D108 and D112 on CR3 labelled I and II – **Fig. 9**). Together with Y209 and R354, they seem to be key for the interaction (**Figs. 10A and B**).

K47 and R354 are key residues of G required for LDL-R CR domains binding

To investigate their contribution to LDL-R CR domains binding, the inventors mutated residues H8, K47, Y209 and R354 of G into an alanine or a glutamine. HEK293T cells were transfected with a plasmid encoding wild-type or mutant VSV G glycoproteins (WT, H8A, K47A, K47Q, Y209A, R354A and R354Q). Twenty-four hours post-transfection, the cells were incubated with a MAb against G ectodomain. Then, green fluorescent anti IgG secondary antibodies and GST-CR fusion proteins fluorescently labelled with ATTO550 were simultaneously added. Immunofluorescence labelling indicated that WT and all G mutants are efficiently transported to the cell surface (**Figs. 11**). Mutants H8A and Y209A bind GST-CR domains as WT G whereas the other mutants are affected in their binding ability (**Figs. 11**). Mutants K47Q, R354A and R354Q bind neither GST-CR2 nor GST-CR3. Finally, although no interaction is detected between mutant K47A and CR3, a residual binding activity is observed between this mutant and CR2 (**Figs. 11**).

The inventors also checked the fusion properties of mutants K47A and R354A. For this, BSR cells were transfected with pCAGGS plasmids encoding wild-type or mutant VSV G glycoproteins (WT, K47A and R354A). The cells expressing mutant G protein have a fusion phenotype similar to that of WT G (**Figs. 13**). This confirms that the mutant glycoproteins are correctly folded and demonstrates that it is possible to decouple G fusion activity and receptor recognition.

Other LDL-R family members are alternative receptors of VSV

HAP-1 cells in which the LDL-R gene has been knocked out (HAP-1 LDL-RKO) (**Fig. 14**) are as susceptible to VSV infection as WT HAP-1 cells (**Fig. 15**). This demonstrates that VSV receptors other than the LDL-R are present at the surface of HAP-1 cells.

To evaluate the role of other LDL-R family members as VSV receptors, the inventors took advantage of the properties of the receptor-associated protein (RAP), a common ligand of all LDL-R family members which blocks ligand binding to all LDL-R family members with the exception of LDL-R itself (Finkelshtein et al., 2013). RAP significantly inhibits VSV infection in HAP-1 LDL-RKO but not in WT HAP-1 cells (**Fig. 15**). Those results are consistent with previous data suggesting that VSV can use other LDL-R family members as alternative receptors (Finkelshtein et al., 2013).

G mutants affected in their CR domain binding site cannot rescue a recombinant VSV lacking the G gene

The inventors then examined whether the mutant glycoproteins described above are able to sustain viral infection. The inventors used a recombinant VSV (VSVΔG-GFP) in which the G envelope gene was replaced by the green fluorescent protein (GFP) gene

and which was pseudotyped with the VSV G glycoprotein. This pseudotyped recombinant was used to infect HEK cells either transfected or not transfected by a plasmid encoding WT or mutant glycoproteins (Ferlin et al., 2014). After 8h, the infected cells supernatant was collected (**Fig. 16**). Mutant glycoproteins incorporation into the envelope of the particles present in the supernatant was verified by western blot (**Fig. 17**) and the infectivity of the pseudotyped particles was analyzed in different cell lines (mammalian HEK, BSR, CHO and Drosophila S2 cells) by counting the cells expressing GFP by flow cytometry 4h post-infection (p.i.) (**Fig. 18**). Mutants K47A, K47Q, R354A and R354Q did not rescue the infectivity of VSV Δ G-GFP. Compared to WT G, the infectivity decreased by a factor of 10 up to 120 (**Fig. 18**). The decrease was more important in HEK and S2 cell lines than in the two hamster cell lines. In mammalian cell lines, mutants H8A and Y209A can rescue the infectivity of VSV Δ G-GFP, but at a lower level than that of WT. In S2 cell line, their infectivity is significantly decreased (by a factor of 15 for mutant H8A and ~6 for Y209A) (**Fig. 18**).

As the fusion activity of the mutants is unaffected, the loss of infectivity of pseudotypes bearing a mutant glycoprotein can be safely attributed to their disability to recognize a cellular receptor. These results indicate that mutants K47A, K47Q, R354A and R354Q which are unable to bind LDL-R CR domains are also severely impaired in their ability to bind other VSV receptors.

Discussion

LDL-R has been demonstrated to be the major entry port of VSV and lentivirus pseudotyped by VSV-G (Finkelshtein et al., 2013). Here, the inventors demonstrate that VSV-G is able to bind two CR domains of the LDL-R with similar affinities. The biological relevance of this interaction was demonstrated by the ability of both CR2 and CR3 to inhibit VSV infection. The crystal structures of VSV G in complex with CR2 and CR3 reveal that they both occupy the same site at the surface of the glycoprotein in its pre-fusion conformation and that the same G residues ensure the correct anchoring of the CR domains. This binding site is split apart when G is in its post-fusion conformation, which explains why G is unable to bind CR domains at low pH. This may disrupt the interaction between G and LDL-R in the endosomal lumen and favour the transport of the virion to an appropriate fusion site.

CR domain recognition by VSV G involves basic residues K47 and R354 pointing toward the calcium-coordinating acidic residues. This mode of binding is very similar to what is observed for endogenous ligand recognition by CR domains of the LDL-R family members and, indeed, mutant glycoproteins in which either K47 or R354 is replaced by an alanine or a glutamine, are unable to bind CR domains. It is worth noting that those key residues are not conserved among vesiculoviruses. Therefore, the use of LDL-R as

a viral receptor cannot be generalized to the other members of the genus. Indeed, the inventors have shown that CHAV G, which does not possess basic residues in positions corresponding to VSV residues 47 and 354, does not bind CR domains.

The inventor's functional analysis confirms that LDL-R is not the only receptor of VSV
5 as HAP-1 LDL-RKO can be infected as efficiently as HAP-1 cells. However, the mutant glycoproteins which are unable to bind CR domains cannot restore VSVΔG-GFP infectivity neither in mammalian nor in insect cells. The most parsimonious interpretation of this result is that the only receptors of VSV in HEK cells are members of the LDL-R family. The molecular basis of the interaction is the same for all those receptors and
10 involves G ability to bind their CR domains. This is in agreement with the decrease of infectivity observed in presence of RAP protein which is an antagonist of other members of the LDL-R family. Overall this study demonstrates that VSV G has specifically evolved to interact with CR domains of the members of the LDL-R family. The ubiquitous nature of this receptor family (which is also widespread among invertebrates) explains the
15 pantropism of VSV.

The demonstration that the receptors of VSV are all members of the LDL-R family together with the characterization of the molecular basis of CR domains recognition by G paves the way to develop recombinant VSVs with modified tropism. Indeed, a glycoprotein having (i) a point mutation which ablates the natural receptor tropism and (ii)
20 an insertion of a protein domain or a peptide targeting specifically a tumor cell (Ammayappan et al., 2013) should allow the design of fully retargeted oncolytic VSVs. Such viruses should be able to eliminate cancerous cells while sparing normal ones.

Cells and viruses

25 BSR, a clone of BHK-21 (Baby Hamster Kidney cells; ATCC CCL-10) and HEK-293T (human embryonic kidney cells expressing simian virus 40 T antigen; ATCC CRL-3216) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). HAP-1 wt and HAP-1 LDL-R deficient cells (HAP-1 LDL-RKO) purchased from Horizon Discovery) were grown in Iscove's Modified Dulbecco's
30 Medium (IMDM) supplemented with 10% FCS. CHO (cell line derived from Chinese hamster ovaries) cells were grown in Ham's F12 medium supplemented with 2mM glutamine and 10% FCS. All mammalian cell lines were maintained at 37°C in a humidified incubator with 5% CO₂. Drosophila S2 cells were grown in Schneider's medium supplemented with 10% FCS at 28°C.

35 Wild-type VSV (Mudd-Summer strain, Indiana serotype), VSVΔG-GCHAV (Rose et al., 2000) and VSV-eGFP were propagated in BSR cells.

VSVΔG-GFP is a recombinant VSV which was derived from a full-length cDNA clone

of the VSV genome (Indiana serotype) in which the coding region of the G protein was replaced by a modified version of the GFP gene and pseudotyped with the VSV G protein (Ferlin et al., 2014). VSVΔG-GFP was propagated on HEK-293T cells that had been previously transfected with pCAGGS-VSVG.

5 **Plasmids and cloning**

Point mutations were created starting from the cloned VSV G gene (Indiana Mudd-Summer strain) in the pCAGGS plasmid. Briefly, forward and reverse primers containing the desired mutation were combined separately with one of the primers flanking the G gene to generate two PCR products. These two G gene fragments overlap in the region
10 containing the mutation and were assembled into the pCAGGS linearized vector using Gibson assembly reaction kit (New England Biolabs).

Protein expression, purification and labelling

VSV Gth was obtained by limited proteolysis of viral particles and purified as previously described (Albertini et al., 2012a).

15 DNA sequences encoding the 7 CR domains of the human LDL-R (NM_000527, GenBank) were synthesized (MWG biotech) and subcloned in the pGEX-6P1 bacterial expression vector (Invitrogen). Each protein construct contains at its N-terminus a GST tag and a preScission protease cleavage site. Each CR domain was purified using the following protocol derived from (Harper and Speicher, 2011). C41 bacteria transformed
20 with the CR construct were cultured at 37° in LB-ampicillin medium until OD reached 0.6 AU. Protein expression was then induced with 1mM IPTG during 5 h at 37°C. Cells were sonicated in lysis buffer (500 mM NaCl, 20 mM Tris-HCl pH 8, 2 mM CaCl₂, 2% w/v sarkosyl and 1mM DTT). The clarified supernatant was incubated with glutathione agarose beads (Thermo Fisher Scientific) in presence of 0.2% Triton X100 during 2h.
25 After incubation, beads were then extensively washed with equilibration buffer (200 mM NaCl, 50 mM Tris HCl pH 8, 2 mM CaCl₂, 1 mM PMSF). The GST-CR construct was then eluted with the same buffer supplemented with 20 mM GSH. Purification of each GST-CR was achieved with a gel filtration step using a Superdex 200 column (Ge Healthcare). To isolate CR domains, purified GST-CR was incubated with preScission protease and
30 injected on a gel filtration column Superdex 75 (Ge Healthcare). Fractions containing pure CR domains were then pooled, concentrated at 1 mM and stored at -80°C until use.

One milligram of purified GST-CR2 (or GST-CR3) was labelled with the fluorescent dye ATTO550 NHS ester (Sigma Aldrich) using the instruction of the manufacturer. The labelled proteins were then diluted at a concentration of 50μM and stored at -80°C until
35 use. The labelling ratio was estimated to be around 2 dyes per molecule.

Characterization of the binding between G and CR domains.

Purified GST-CR domains were incubated with magnetic beads coated with GSH

(Eurogentec) under agitation during 20 min at 4°C. Then, the slurry was washed with the equilibration buffer at the appropriate pH (200 mM NaCl, 2 mM CaCl₂, 50mM Tris-HCl pH 8 or 50 mM MES-NaOH pH 6). Purified Gth or viral particles were preincubated in this same buffer for 20 min and added to the magnetic beads bound to GST-CR construction or GST alone. After 20 min of incubation under soft agitation, the slurry was washed two times with the equilibration buffer at the appropriate pH (either 8 or 6). Beads were re-suspended in the gel loading buffer and directly analyzed on a SDS PAGE.

Binding of CR domains to cells expressing G (either WT or mutants)

For microscopy, BSR cells were infected for 4h and were then incubated with GST-CR2ATTO550 or GST-CR3ATTO550 at 4°C for 30 min. Cells were fixed with 4% paraformaldehyde and then permeabilized with 0.5 % Triton X-100. Nucleoprotein was detected by using a mouse monoclonal anti-VSV N antibody. Goat anti-mouse Alexa fluor 488 (Invitrogen) was used as a secondary antibody. Images were captured using a Leica SP8 confocal microscope (63X oil-immersion objective).

For flow cytometry experiments, HEK-293T cells were transfected with pCAGGS plasmids encoding WT or mutant G using polyethylenimine (PEI, Sigma-Aldrich). 24h after transfection, cells were collected and incubated with a mouse-monoclonal anti-G antibody that recognizes G ectodomain (8G5F11, KeraFast). Goat anti-mouse Alexa fluor 488 and GST-CR2ATTO550 (or GST-CR3ATTO550) were then simultaneously added to the cells. The fluorescence of cells was determined using a BD Accuri C6 flow cytometer.

Pseudotypes

HEK-293T cells at 80% confluence were transfected by pCAGGS encoding WT or mutant VSV G using PEI. At 24h after transfection, cells were infected with VSVΔG-GFP at an MOI of 1. Two hours p.i., cells were washed to remove residual viruses from the inoculum. Cell supernatants containing the pseudotyped viral particles were collected at 16h p.i. The infectious titers of the pseudotyped viruses were determined on non-transfected cells by counting cells expressing the GFP using a BD Accuri C6 flow cytometer at 4h p.i. WT and mutant G incorporation in the pseudotyped particles was assessed after supernatant concentration by SDS PAGE and western blot analysis using an anti-VSV G and an anti-VSV M.

HAP-1 cells infection

HAP-1 cells were plated at 70% confluence and incubated, or not, with 50nM of RAP during 15 min. Cells were then infected with VSV-eGFP at an MOI of 1. RAP was maintained during all the infection time. The percentage of infected cells (GFP-positive) was determined 4h p.i. using a BD Accuri C6 flow cytometer.

ITC

ITC experiments were performed at 293 K using a MicroCal iTC200 apparatus (GE

Healthcare) in a buffer composed of 150 mM NaCl, 20 mM Tris-HCl pH 8.0 and 2mM CaCl₂. Gth, at a concentration of 50 μ M, was titrated by successive injections of CR domains at a concentration of 600 μ M. The titration sequence included a first 1 μ L injection followed by 19 injections of 2 μ L each with a spacing of 180 or 240 s between
5 injections. OriginLab software (GE Healthcare) was used to analyze the raw data. Binding parameters were extracted from curve fitting analysis with a single-site binding model.

Cell-cell fusion assay

Cell-cell fusion assay was performed as previously described (Ferlin et al., 2014). Briefly, BSR cells plated on glass coverslips at 70% confluence were co-transfected with
10 pCAGGS plasmids encoding WT G or mutant G, and P-GFP plasmid encoding the phosphoprotein of Rabies virus fused to GFP. Twenty four hours after transfection, cells were incubated with fusion buffer (DMEM-10mM MES) at various pHs (from 5.0 to 7.5) for 10 minutes at 37°. Cells were then washed once and incubated with DMEM-10mM HEPES-NaOH buffered at pH 7.4, 1% BSA at 37°C for 1 hour. Cells were fixed with 4%
15 paraformaldehyde in 1× PBS for 15 min. Cells nuclei were stained with DAPI and syncytia formation was analyzed with Zeiss Axiovert 200 fluorescence microscope with a 10× lens.

Bibliography

- Albertini, A.A.V., Baquero, E., Ferlin, A., and Gaudin, Y. (2012b). Molecular and Cellular Aspects of Rhabdovirus Entry. *Viruses* 4, 117-139.
- 20 Amirache, F., Levy, C., Costa, C., Mangeot, P.E., Torbett, B.E., Wang, C.X., Negre, D., Cosset, F.L., and Verhoeyen, E. (2014). Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. *Blood* 123, 1422-1424.
- Ammayappan, A., Peng, K.W., and Russell, S.J. (2013). Characteristics of oncolytic
25 vesicular stomatitis virus displaying tumor-targeting ligands. *J Virol* 87, 13543-13555.
- Barber, G.N. (2005). VSV-tumor selective replication and protein translation. *Oncogene* 24, 7710-7719.
- Ferlin, A., Raux, H., Baquero, E., Lepault, J., and Gaudin, Y. (2014). Characterization of pH-sensitive molecular switches that trigger the structural transition of vesicular
30 stomatitis virus glycoprotein from the postfusion state toward the prefusion state. *J Virol* 88, 13396-13409.
- Finkelstein, D., Werman, A., Novick, D., Barak, S., and Rubinstein, M. (2013). LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. *Proceedings of the National Academy of Sciences of the United States of America*
35 110, 7306-7311.
- Roche, S., Bressanelli, S., Rey, F.A., and Gaudin, Y. (2006). Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. *Science* 313, 187-191.

Roche, S., Rey, F.A., Gaudin, Y., and Bressanelli, S. (2007). Structure of the prefusion form of the vesicular stomatitis virus glycoprotein g. *Science* 315, 843-848.

Example 2 : Preparation of plasmid encoding modified G

Construction of pCAGGS plasmids containing the desired coding G sequence with the mCherry inserted at various position were generated using Gibson assembly reaction. The empty vector pCAGGS was linearized using EcoRI restriction enzyme. Then 3 PCR products with overlapping parts were generated. The product I is the fragment of G before the insertion site; it is generated running a PCR on the VSV G gene using primers Ia and Ib₁ to insert the mCherry in position 1 or Ia and Ib₃₅₁ to insert the mCherry in position 351. The product II is the mCherry gene (using primers IIa₁ and IIb₁ to insert the mCherry in position 1 or IIa₃₅₁ and IIb₃₅₁ to insert the mCherry in position 351). The product III is the fragment of G after the insertion site; it is generated using primers IIIa₁ and IIIb to insert the mCherry in position 1 or IIIa₃₅₁ and IIIb to insert the mCherry in position 351.

Primer sequences were synthesized by Eurofins Genomics:

Ia : TCTCATCATTTTGGCAAAGATGAAGTGCCTTTTGTACTTAG (SEQ ID NO : 332)
 Ib₁: TTGCTCACCATGCAATTCACCCCAATGAATAAAAAG (SEQ ID NO: 333)
 Ib₃₅₁: GCTCACCATAGTTCCACTGATCATTCCGACC (SEQ ID NO: 334)
 IIa₁: CATTGGGGTGAATTGCATGGTGAAGCAAGGGC (SEQ ID NO: 335)
 IIa₃₅₁: AATGATCAGTGGAAGTATGGTGAAGCAAGGGC (SEQ ID NO: 336)
 IIb₁: AAAILb1CTATGGTGAAGTCTTGTACAGCTCGTCC (SEQ ID NO: 337)
 IIb₃₅₁: GTTCCCTTTCTGTGGTCTTGTACAGCTCGTCC (SEQ ID NO: 338)
 IIIa₁: GAGCTGTACAAGAAGTTCACCATAGTTTTTCCACACA (SEQ ID NO: 339)
 IIIa₃₅₁: CTGTACAAGACCACAGAAAGGGAAGTGT (SEQ ID NO: 340)
 IIIb: CCGCCCGGGAGCTCGTTACTTTCCAAGTCGGTTC (SEQ ID NO: 341)

After purification of each fragment on agarose gel, the 3 fragments plus the purified digested pCAGGS vector are then combined in equimolar concentration and assembled by Gibson assembly reaction. The DNA is then transformed into bacteria, and a correct plasmid product amplified after been identified by restriction digest and/or sequencing.

Example 3: Transient expression of modified VSV glycoproteins:

The transfection protocol will depend of the kind of cells to transduce. For HEK cells the inventors use PolyEthylenimine (PEI) transfection protocol. For BHK the inventors use Ca-Phosphate transfection protocol or PEI.

Cells grown on coverslips were transfected with pCAGGS plasmid encoding for VSV modified glycoprotein. After 20 hour of transfection the cells were fixed with 4% paraformaldehyde in PBS. After washing (3 times with PBS) coverslips were mounted with immu-mount DAPI (thermofisher) and examined with a Zeiss microscope. Red fluorescence is present at the cell surface in both case indicating that the protein was

correctly folded through the Golgi apparatus (Figure 19).

The invention is not limited to the above-mentioned embodiments.

Claims

1. An isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO : 1, which is the amino acid sequence of the ectodomain of VSV Indiana strain,
- 5 wherein at least one of the amino acids at positions 8, 47, 209 and 354, said numbering being made from the position of the first amino acid in the sequence SEQ ID NO: 1, is substituted by an amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1,
- 10 wherein the substitution at position 8 is by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1, except Y, and
- wherein the substitution at position 209 is by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1, except H,
- 15 or any homologous protein derived from said protein as set forth in SEQ ID NO : 1 by substitution, addition or deletion of at least one amino acid, provided that the derived protein retains at least 70 % of identity with the amino acid sequence as set forth in SEQ ID NO : 1, and said derived protein retaining the ability to induce membrane fusion and retaining the ability to interact with LDL membrane receptor,
- 20 wherein at least one amino acid, of said homologous protein located at a position equivalent to the positions 8, 47, 209 and 354 of said sequence SEQ ID NO : 1, is substituted by an amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1,
- wherein the substitution of the amino acid located at a position equivalent to the position 8 is by any amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1, except Y, and
- 25 wherein the substitution of the amino acid located at a position equivalent to the position 209 is by any amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1, except H,
- 30 said isolated non-naturally occurring protein retaining the ability to induce membrane fusion and being unable to interact with LDL membrane receptor.
2. The isolated non naturally occurring protein according to claim 1, wherein said protein comprises one of the following amino acid sequence :
- 35 - SEQ ID NO : 15-20 ;
- SEQ ID NO : 21-26 ;
- SEQ ID NO : 27-32 ;

- SEQ ID NO : 33-38 ;
- SEQ ID NO : 39-44 ;
- SEQ ID NO : 45-50 ; and
- SEQ ID NO : 51-56.

5

3. The isolated non-naturally occurring protein according to claim 1 or 2, wherein the amino acid at position 47 or at position 354, or at both positions 47 and 354 are substituted by any amino acid except K or R, in particular by A, G, F or Q, preferably by A or Q.

10

4. The isolated non-naturally occurring protein according to claim 3, further comprising a substitution of the amino acid at position 8 and/or at position 209 by any amino acid distinct from the amino acid indicated at that position in the sequence SEQ ID N° 1 or at the position equivalent in said homologous protein.

15

5. The isolated non-naturally occurring protein according to any one of claims 1 to 4, wherein the amino acid at position 8 is substituted by any amino acid except H or Q or Y.

20

6. The isolated non-naturally occurring protein according to any one of claims 1 to 5, wherein the amino acid at position 209 is substituted by any amino acid except Y or H.

25

7. The isolated non-naturally occurring protein according to any one 1 to 6, wherein said protein comprises of one of the following amino acid sequence SEQ ID NO : 57-154.

30

8. The isolated non-naturally occurring protein according to any one of claims 1 to 7, further comprising an insertion of a peptide between the amino acids at positions:
- 192 to 202, or
 - 240 to 257, or
 - 347 to 353, or
 - 364 to 366, or
 - 376 to 379,

35

- said peptide originating from a peptide different from the protein as set forth in SEQ ID NO : 1.

9. The isolated non-naturally occurring protein according to any one of claims 1 to 7, further comprising an insertion of a peptide in position 1 or between the amino acids at position 351 and 352, said peptide originating from a protein different from the protein as set forth in SEQ ID NO : 1.
- 5
10. The isolated non-naturally occurring protein according to claim 8 or 9, wherein said peptide is at least a part of a ligand of a cellular receptor, preferably a nanobody, for instance an anti-HER2 nanobody, an anti-MUC18 nanobody or an anti-PD-1 nanobody.
- 10
11. A nucleic acid molecule coding for an isolated non-naturally occurring protein as defined in any one of claims 1 to 10.
12. A recombinant virus expressing an isolated non-naturally occurring protein as defined in any one of claims 1 to 10.
- 15
13. A recombinant virus comprising a nucleic acid molecule as defined in claim 11.
14. A eukaryotic cell containing or expressing a non-naturally occurring protein as defined in any one of claims 1 to 10, or containing a nucleic acid molecule as defined in claim 11, or infected by a virus as defined in claim 12 or 13.
- 20
15. A composition comprising one at least of the followings:
a protein according to any one of claims 1 to 10; or
a nucleic acid molecule as defined in claim 11
25 a virus according to claim 12 or 13; or,
a eukaryotic cell according to claim 14,
for its use as drug.
16. The composition according to claim 15, for its use for treating cancer.
- 30
17. An *in vitro* use of a protein according to any one of claims 1 to 10 for targeting a lipid membrane to a specific target, for instance a cell, in particular a cell to be killed, such as a cancer cell, wherein said protein is anchored in said lipid membrane.
- 35
18. A protein according to any one of claims 1 to 10, for use for targeting a lipid

membrane to a specific target, for instance a cell, in particular a cell to be killed, such as a cancer cell, wherein said protein is anchored in said lipid membrane.

1/10




Fig. 1




Fig. 2





Fig. 3

2/10



Figs. 4





Fig. 5

3/10



Figs. 6




Fig. 7

4/10




Fig. 8






Fig. 9

5/10



Figs. 10



Figs. 11

6/10





Fig. 12



Figs. 13

7/10




Fig. 14




Fig. 15

8/10




Fig. 16

9/10




Fig. 17





Fig. 18

10/10



Figs. 19

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/075824

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K14/005 C12N7/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	NIKOLIC J ET AL: "Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein", NATURE COMMUNICATIONS, vol. 9, no. 1, 12 March 2018 (2018-03-12), pages 1-12, XP055518690, DOI: 10.1038/s41467-018-03432-4 abstract; results; discussion; -----	1-18
Y	WO 01/19380 A2 (PRO VIRUS INC [US]) 22 March 2001 (2001-03-22) page 1; claims; figure 21; examples -----	1-18
Y	US 2008/124357 A1 (YAO JIANSHENG [CA] ET AL) 29 May 2008 (2008-05-29) claims; examples; sequence 17 ----- -/--	1-18



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

12 November 2018

Date of mailing of the international search report

28/11/2018

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Sommer, Birgit

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2018/075824

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AMMAYAPPAN A ET AL: "Characteristics of Oncolytic Vesicular Stomatitis Virus Displaying Tumor-Targeting Ligands", JOURNAL OF VIROLOGY., vol. 87, no. 24, 2 October 2013 (2013-10-02), pages 13543-13555, XP055122167, US ISSN: 0022-538X, DOI: 10.1128/JVI.02240-13 abstract; results; discussion;; figures -----	1-15
A	FINKELSHTEIN D ET AL: "LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 110, no. 18, 15 April 2013 (2013-04-15), pages 7306-7311, XP055436675, US ISSN: 0027-8424, DOI: 10.1073/pnas.1214441110 abstract; results; discussion; -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2018/075824

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0119380	A2	22-03-2001	AT 319460 T 15-03-2006
		AT 418341 T 15-01-2009	
		AU 782402 B2 28-07-2005	
		CA 2386920 A1 22-03-2001	
		CN 1496268 A 12-05-2004	
		DE 60026554 T2 28-09-2006	
		EP 1218019 A2 03-07-2002	
		EP 1716858 A2 02-11-2006	
		ES 2260057 T3 01-11-2006	
		ES 2320239 T3 20-05-2009	
		HK 1044708 A1 27-10-2006	
		HK 1092713 A1 26-06-2009	
		IL 148621 A 17-02-2010	
		JP 5060694 B2 31-10-2012	
		JP 2004525855 A 26-08-2004	
		MX PA02002772 A 02-04-2004	
		NZ 517573 A 27-02-2004	
		NZ 523805 A 24-09-2004	
		NZ 534306 A 23-12-2005	
		NZ 534307 A 29-07-2005	
		WO 0119380 A2 22-03-2001	

US 2008124357	A1	29-05-2008	US 2008124357 A1 29-05-2008
			WO 2008097267 A2 14-08-2008
